Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-24-100993
Filing Date
2024-11-21
Accepted
2024-11-21 16:15:10
Documents
15
Period of Report
2024-04-01
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 TO FORM 8-K ea0221909-8ka3_aditxt.htm   iXBRL 8-K/A 38076
2 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF APPILI THERAPEUTICS, IN ea022190901ex99-1_aditxt.htm EX-99.1 254662
3 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION AS OF AND FOR THE NINE MO ea022190901ex99-2_aditxt.htm EX-99.2 552126
  Complete submission text file 0001213900-24-100993.txt   1096214

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adtx-20240401.xsd EX-101.SCH 3009
5 XBRL LABEL FILE adtx-20240401_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE adtx-20240401_pre.xml EX-101.PRE 22355
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0221909-8ka3_aditxt_htm.xml XML 9240
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39336 | Film No.: 241484539
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)